“Start low, go slow”: the rule guiding the safe use of medicinal cannabis

When a patient starts treatment with medicinal cannabis, a phrase often appears right at the first consultation: “Start low, go slow.” The advice, repeated by doctors in different countries, summarizes an approach that prioritizes safety, personalization, and respect for the biological rhythm of each organism.

Translated as “start low and go slow,” the method guides to begin with small doses and increase gradually. The idea is simple but fundamental: observe how the body reacts and avoid both unwanted effects and lack of efficacy.

Doctor Beatriz Jacob Milani, who works in chronic pain treatment and is a student of medicinal cannabis, explains that this principle is one of the pillars of good clinical practice. “‘Start low, go slow’ means starting with low doses and increasing progressively, allowing to find the minimum effective dose, with safety and good tolerability,” she states.

According to Beatriz, the strategy makes sense because the endocannabinoid system works very uniquely in each person. Genetics, body composition, age, comorbidities, and even how each organism metabolizes phytocannabinoids directly influence the treatment response. “The endocannabinoid system is highly individual, and this requires careful management from the beginning,” she emphasizes.

Adjustments made step by step

In clinical monitoring, the logic also remains: slow and steady wins the race. Dose adjustments are made based on the patient's response, whether there has been pain improvement, better sleep quality, anxiety reduction, or control of the symptom that led to the prescription. All this without losing sight of tolerability.

“When adjusting the dose, we mainly observe the clinical response and possible adverse effects,” explains the doctor. She highlights that other factors come into play, such as age, presence of associated diseases, drug interactions, and the type of product used, whether it is an isolated CBD or extracts with different proportions of phytocannabinoids.

This gradual monitoring allows reaching the so-called “lowest effective dose,” the point where the patient achieves the desired benefit with minimal risks. “The slow adjustment ensures a safer, personalized, and consistent treatment with interindividual variability,” she concludes.